Esperion Therapeutics Inc
$ 2.05
-7.66%
14 Apr - close price
- Market Cap 570,119,000 USD
- Current Price $ 2.05
- High / Low $ 2.27 / 2.03
- Stock P/E N/A
- Book Value -1.23
- EPS -0.11
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE -2.61 %
- 52 Week High 4.17
- 52 Week Low 0.69
About
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Analyst Target Price
$6.99
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-13 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-12 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-01 | 2023-05-09 |
| Reported EPS | 0.22 | -0.16 | -0.06 | -0.2063 | -0.1013 | -0.15 | -0.33 | 0.34 | -0.5 | -0.37 | -0.46 | -0.79 |
| Estimated EPS | 0.2916 | 0.02 | -0.14 | -0.15 | -0.1575 | -0.18 | -0.18 | 0.05 | -0.48 | -0.43 | -0.61 | -0.65 |
| Surprise | -0.0716 | -0.18 | 0.08 | -0.0563 | 0.0562 | 0.03 | -0.15 | 0.29 | -0.02 | 0.06 | 0.15 | -0.14 |
| Surprise Percentage | -24.5542% | -900% | 57.1429% | -37.5333% | 35.6825% | 16.6667% | -83.3333% | 580% | -4.1667% | 13.9535% | 24.5902% | -21.5385% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ESPR
2026-04-14 10:39:54
Needham has reiterated its Buy rating for Esperion Therapeutics (ESPR.US) and maintained its price target of $5. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-04-13 23:38:54
Esperion Therapeutics presented at Needham & Company’s 25th Annual Healthcare Conference, reporting 38% year-over-year revenue growth and highlighting a recent guideline update that provides multiple Class 1A recommendations for its bempedoic acid therapies. The company also detailed the acquisition of Corstasis and its nasally delivered loop diuretic, Enbumyst, with commercial launch planned for September 2026, and outlined pipeline updates including a triple-combination LDL therapy and a primary sclerosing cholangitis program.
2026-04-13 16:38:54
Esperion Therapeutics is advocating for the broader integration of high-sensitivity C-reactive protein (hsCRP) in cardiovascular care. The company asserts that hsCRP is a crucial biomarker for identifying residual inflammatory risk in patients, even those who have achieved their LDL-C targets. This move aims to promote more personalized and biomarker-driven approaches to heart health management.
2026-04-09 01:39:14
This article provides an in-depth analyst forecast for ESPERION THERAPEUTICS INC (ESPR), noting a consensus price target of $6.86, suggesting a 215.99% upside. It details future earnings estimates, projecting Q1 2026 EPS at -$0.03 and revenue at $96.129M, alongside a ChartMill Buy Consensus Rating of 78.57%. The report also includes historical analyst ratings, recent upgrades/downgrades, and long-term growth forecasts for EPS, revenue, and EBIT.
2026-04-07 16:09:01
Esperion Therapeutics Inc. (ESPR) stock dipped by 11.57% after its Q4 EPS of $0.22 missed analyst estimates of $0.27. This disappointing earnings report, despite revenues exceeding $403 million, has raised concerns among investors about the company's financial performance, profitability margins, and competitive challenges. Market analysts are closely watching Esperion's strategic responses to address liquidity constraints and high research costs.
2026-04-07 08:40:16
Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received a "Moderate Buy" consensus rating from eight analysts, with an average one-year price target of $7.60. Despite missing EPS estimates slightly, the company exceeded revenue expectations. Institutional investors, including Vanguard and State Street, have increased their stakes, with institutions now owning approximately 47.39% of the company.
